Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS).
about
Early functional deficit and microglial disturbances in a mouse model of amyotrophic lateral sclerosisTempol moderately extends survival in a hSOD1(G93A) ALS rat model by inhibiting neuronal cell loss, oxidative damage and levels of non-native hSOD1(G93A) formsViral delivery of antioxidant genes as a therapeutic strategy in experimental models of amyotrophic lateral sclerosis.Semaphorin 3A signaling through neuropilin-1 is an early trigger for distal axonopathy in the SOD1G93A mouse model of amyotrophic lateral sclerosisEarly detection of motor dysfunction in the SOD1G93A mouse model of Amyotrophic Lateral Sclerosis (ALS) using home cage running wheels.Perturbations in intracellular Ca2+ handling in skeletal muscle in the G93A*SOD1 mouse model of amyotrophic lateral sclerosis.S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosisActivation of the endoplasmic reticulum stress response in skeletal muscle of G93A*SOD1 amyotrophic lateral sclerosis mice.Lysosomal and phagocytic activity is increased in astrocytes during disease progression in the SOD1 (G93A) mouse model of amyotrophic lateral sclerosis.Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis.Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part I, background and methods.Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part II, results and discussionMolecular pathways of motor neuron injury in amyotrophic lateral sclerosis.Viral delivery of C9orf72 hexanucleotide repeat expansions in mice leads to repeat-length-dependent neuropathology and behavioural deficits.Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis.C9orf72 expansion disrupts ATM-mediated chromosomal break repair.Early ALS-type gait abnormalities in AMP-dependent protein kinase-deficient mice suggest a role for this metabolic sensor in early stages of the disease.Measurement of mechanical withdrawal thresholds and gait analysis using the CatWalk method in a nucleus pulposus-applied rodent model.Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model.Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis.Degeneration of proprioceptive sensory nerve endings in mice harboring amyotrophic lateral sclerosis-causing mutations.qMotor, a set of rules for sensitive, robust and quantitative measurement of motor performance in mice.Administration of 17β-Estradiol Improves Motoneuron Survival and Down-regulates Inflammasome Activation in Male SOD1(G93A) ALS Mice.MRI reveals therapeutical efficacy of stem cells: An experimental study on the SOD1(G93A) animal model.Postnatal Development of Spasticity Following Transgene Insertion in the Mouse βIV Spectrin Gene (SPTBN4).Multiple systemic transplantations of human amniotic mesenchymal stem cells exert therapeutic effects in an ALS mouse model.Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS.
P2860
Q27303916-CF3156F3-FFA2-46DD-B680-310ACC3C7E36Q27315986-63EDB7B6-B3A4-4FB3-AA6F-6DD6438E8159Q30542282-EF8FFF4E-49AC-496C-BAE1-573CE83D3FA1Q33811484-77D77287-C7BF-4CE2-9E34-901484EB5CB8Q34276554-5ED659CD-4BDC-45D4-8DA0-7D8EB4BFE175Q34627484-AC8FD6F1-4E42-409F-86A2-155D230D8D2BQ34680962-B1A0690B-4F02-41FE-8597-CEFCFABB6580Q35617613-D1BD9FFA-D324-4D6D-B41E-77C7262D663DQ35830165-F0EEB585-B249-44F1-A99E-2684F9B440D5Q37363769-343D2654-CC5D-477E-8EBC-06D2BB6E15C3Q37407284-7128E330-3C6D-4395-A15A-B8D89DA7587FQ37407302-14EEA6A8-CD04-4064-BC5F-A69C6F0B2E1EQ37952528-BFE491A4-0330-4AC1-A806-5C4D2B108645Q38760731-6494574B-2815-4854-BA08-FFEA13DE7F45Q39215660-A3F6ECC4-9830-4D8C-815A-446CB8ED9A5BQ40120242-9A3F188A-640C-44C5-B167-54F9C0572583Q40760240-30520EB2-73D6-4785-8C73-F03D64D61415Q42369052-F6C51F03-063B-410E-8D5E-FD4DD732B110Q42749841-9A169D7D-8BC2-4FE2-AFEB-D63A12C52335Q44704967-785FADC4-1529-400B-9D32-F1AC28B698E4Q45015781-3244A4E1-9C7C-4A33-8271-4ED5C1A042C8Q47158166-1E51035A-218C-41A7-8858-9A85F0B7605CQ48161670-5B04D2C7-C2E3-4900-B122-1FF7DFD6E60AQ48233346-9CF1E25E-B7F7-413C-B1D8-9FADE4F82C46Q48598304-571A4722-366E-40AC-BAB5-054EAB8D0A6FQ48729092-6D711131-EBD9-4CCD-B87F-C7DEF91993BFQ55399094-F89E59D6-809F-4CCB-B30F-7DAC61C082C6
P2860
Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS).
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Optimised and rapid pre-clinical screening in the SOD1
@nl
Optimised and rapid pre-clinic ...... ophic lateral sclerosis (ALS).
@ast
Optimised and rapid pre-clinic ...... ophic lateral sclerosis (ALS).
@en
type
label
Optimised and rapid pre-clinical screening in the SOD1
@nl
Optimised and rapid pre-clinic ...... ophic lateral sclerosis (ALS).
@ast
Optimised and rapid pre-clinic ...... ophic lateral sclerosis (ALS).
@en
prefLabel
Optimised and rapid pre-clinical screening in the SOD1
@nl
Optimised and rapid pre-clinic ...... ophic lateral sclerosis (ALS).
@ast
Optimised and rapid pre-clinic ...... ophic lateral sclerosis (ALS).
@en
P2093
P2860
P50
P1433
P1476
Optimised and rapid pre-clinic ...... rophic lateral sclerosis (ALS)
@en
P2093
Aneurin J Kennerley
Brigitte Pettmann
Claire Sunyach
Jason Berwick
Paul Sharp
P2860
P304
P356
10.1371/JOURNAL.PONE.0023244
P407
P50
P577
2011-08-18T00:00:00Z